Aprepitant in the Management of Biological Therapies-related Severe Pruritus
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
Itch is a common side effect of anti-epidermal growth factor receptor antibodies and tyrosine
kinase inhibitors. Investigators designed a pilot single-center phase II study evaluating the
effects of Aprepitant, a neurokinin receptor inhibitor, in managing biological
therapy-induced pruritus.